Table 3.
Impact of MetS components on coronary collateral growth in patients with and without MetS
| Variables | Quartiles of components | Non-MetS | MetS | All | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Range | n | Good/Poor | OR (95%CI) | P Value | Good/Poor | OR (95%CI) | P Value | Good/Poor | OR (95%CI) | P Value | |
| HT, n(%) | – | 1071 | 73/319 | 1.386 (0.758–2.534) | 0.289 | 182/497 | 1.478 (0.881–2.481) | 0.139 | 255/816 | 1.179 (0.818–1.699) | 0.377 |
| T2DM, n(%) | – | 570 | 38/129 | 2.292 (0.886–5.929) | 0.087 | 118/285 | 1.718 (0.988–2.987) | 0.055 | 156/414 | 1.664 (1.053–2.629) | 0.029 |
| BMI, Kg/m2 | Per quartile | 1653 | 140/672 | 1.897 (1.458–2.467) | < 0.001 | 230/667 | 1.814 (1.482–2.220) | < 0.001 | 370/1339 | 1.755 (1.510–2.038) | < 0.001 |
| Q1 ≤ 24.33 | 412 | 19/225 | – | – | 21/137 | – | – | 40/362 | – | – | |
| 24.33 < Q2 ≤ 26.29 | 415 | 30/187 | 6.413 (2.679–15.354) | < 0.001 | 30/168 | 5.424 (2.688–10.943) | < 0.001 | 60/355 | 4.852 (2.934–8.024) | < 0.001 | |
| 26.29 < Q3 ≤ 28.37 | 413 | 54/164 | 4.330 (1.952–9.604) | < 0.001 | 54/141 | 4.399 (2.467–7.844) | < 0.001 | 108/305 | 3.594 (2.324–5.560) | < 0.001 | |
| 28.37 < Q4 | 413 | 30/72 | 1.720 (0.847–3.490) | 0.133 | 117/194 | 1.768 (1.085–2.940) | 0.023 | 147/266 | 1.464 (1.010–2.121) | 0.044 | |
| TG, mmol/L | Per quartile | 1653 | 1.664 (1.264–2.190) | < 0.001 | 1.407 (1.136–1.744) | 0.002 | 370/1339 | 1.371 (1.184–1.588) | < 0.001 | ||
| Q1 ≤ 1.08 | 412 | 30/275 | – | – | 20/87 | – | – | 50/362 | – | – | |
| 1.09 < Q2 ≤ 1.44 | 421 | 57/225 | 5.940 (2.203–16.012) | < 0.001 | 28/111 | 2.324 (1.097–4.927) | 0.028 | 85/336 | 2.764 (1.694–4.510) | < 0.001 | |
| 1.44 < Q3 ≤ 2.07 | 410 | 30/119 | 2.093 (0.822–5.311) | 0.121 | 71/190 | 2.750 (1.422–5.320) | 0.003 | 101/309 | 1.609 (1.040–2.491) | 0.033 | |
| 2.07 < Q4 | 410 | 16/39 | 2.087 (0.806–5.400) | 0.129 | 103/252 | 1.149 (0.727–1.816) | 0.551 | 119/291 | 1.161 (0.790–1.706) | 0.447 | |
| HDL-C, mmol/L | Per quartile | 1653 | 0.970 (0.751–1.252) | 0.812 | 0.918 (0.741–1.137) | 0.431 | 370/1339 | 1.006 (0.866–1.168) | 0.937 | ||
| Q1 ≤ 0.84 | 414 | 20/85 | – | – | 83/226 | – | – | 103/311 | – | – | |
| 0.84<Q2≤0.98 | 408 | 21/99 | 0.893 (0.396–2.015) | 0.786 | 69/219 | 0.751 (0.345–1.631) | 0.469 | 90/318 | 1.092 (0.679–1.756) | 0.715 | |
| 0.98<Q3 ≤ 1.16 | 412 | 38/194 | 1.179 (0.524–2.651) | 0.691 | 45/135 | 0.882 (0.407–1.912) | 0.751 | 83/329 | 1.241 (0.775–1.989) | 0.368 | |
| 1.16<Q4 | 419 | 54/280 | 1.558 (0.794–3.055) | 0.197 | 25/60 | 0.938 (0.416–2.114) | 0.877 | 79/340 | 1.223 (0.761–1.965) | 0.406 | |
| SBP, mmHg | Per quartile | 1653 | 1.162 (0.858–1573) | 0.333 | 1.362 (1.078–1.720) | 0.010 | 370/1339 | 1.252 (1.049–1.496) | 0.013 | ||
| Q1 ≤ 119 | 425 | 32/199 | – | – | 31/163 | - | – | 63/362 | – | – | |
| 119<Q2≤128 | 412 | 39/181 | 1.715 (0.631–4.664) | 0.290 | 38/154 | 2.438 (1.140–5.215) | 0.022 | 77/335 | 1.975 (1.121–3.478) | 0.019 | |
| 128<Q3 ≤ 137 | 400 | 29/148 | 1.215 (0.519–2.844) | 0.653 | 62/161 | 1.915 (1.016–3.610) | 0.044 | 91/309 | 1.601 (0994–2.579) | 0.053 | |
| 137<Q4 | 416 | 33/130 | 1.270 (0.546–2.956) | 0.579 | 91/162 | 1.215 (0.712–2.072) | 0.475 | 124/292 | 1.319 (0.862–2.019) | 0.202 | |
| DBP, mmHg | Per quartile | 1653 | 1.089 (0.806–1.471) | 0.579 | 1.287 (1.024–1.617) | 0.030 | 370/1339 | 1.202 (1.010–1.430) | 0.038 | ||
| Q1 ≤ 69 | 381 | 27/168 | – | – | 37/149 | – | – | 64/317 | – | – | |
| 69<Q2≤75 | 424 | 37/191 | 1.439 (0.531–3.901) | 0.640 | 37/159 | 1.905 (0.939–3.865) | 0.074 | 74/350 | 1.769 (1.029–3.044) | 0.039 | |
| 75<Q3 ≤ 82 | 417 | 33/178 | 1.630 (0.692–3.838) | 0.288 | 45/161 | 2.711 (1.437–5.135) | 0.002 | 78/339 | 1.967 (1.230–3.146) | 0.005 | |
| 82<Q4 | 431 | 36/121 | 1.848 (0.796–4.292) | 0.153 | 103/171 | 2.794 (1.573–4.963) | < 0.001 | 139/292 | 2.215 (1.415–3.465) | < 0.001 | |
| FBG, mmol/L | Per quartile | 1709 | 1.018 (0.735–1.409) | 0.917 | 1.006 (0.817–1.238) | 0.955 | 370/1339 | 0.968 (0.825–1.136) | 0.691 | ||
| Q1 ≤ 5.12 | 420 | 47/233 | – | – | 36/104 | – | – | 83/337 | – | ||
| 5.12<Q2≤5.76 | 410 | 38/244 | 1.505 (0.499–4.542) | 0.468 | 27/101 | 1.047 (0.540–2.029) | 0.892 | 65/345 | 0.922 (0.565–1.505) | 0.745 | |
| 5.76<Q3 ≤ 7.33 | 411 | 22/101 | 2.354 (0.745–7.442) | 0.145 | 68/220 | 1.193 (0.614–2.320) | 0.603 | 90/321 | 1.305 (0.787–2.163) | 0.302 | |
| 7.33<Q4 | 412 | 26/80 | 1.654 (0.577–4.745) | 0.349 | 91/215 | 1.042 (0.628–1.730) | 0.873 | 117/295 | 1.156 (0.748–1.786) | 0.514 | |
OR odds ratio, CIconfdence interval, MetS Metabolic Syndrome, BMI body mass index, HT Hypertension, T2DM type 2 diabetes mellitus, HDL-C high-density lipoprotein cholesterol, TG Triglycerides, FBG Fasting blood glucose, SBP systolic blood pressure, DBP diastolic blood pressure
aMultiple adjustment for adjusted for age, sex, heart rate, renal disease, former smoker, current smoker, prior myocardial infarction, stroke, history of percutaneous coronary intervention, white blood cell, homocysteine, platelet, creatinine, eGFR, glycated albumin, uric acid, ventricular ejection fraction; left ventricular end-diastolic dimension; left ventricular end-systolic dimension, Diuretics, ACE inhibitors/ARBs,β-blockers, CCBs, hypoglycemic agents